SNGX: Additional Positive Outcomes in Investigator-Initiated Study of HyBryte in CTCL
On January 14, 2025, Soligenix, Inc. (SNGX) announced additional interim data from the open-label, investigator-initiated study (IIS) testing...
236 Views
SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway
On December 16, 2024, Soligenix, Inc. (SNGX) announced it has opened patient enrollment for the confirmatory Phase 3 FLASH2 (Fluorescent Light...
296 Views
SNGX: Marburg Outbreak Puts Focus on Soligenix Vaccine Development
On October 2, 2024, two travelers in Hamburg, Germany were hospitalized due to displaying symptoms consistent with Marburg virus. The two...
337 Views
SNGX: Phase 3 Trial of HyBryte in CTCL to Initiate in 2H24
On August 9, 2024, Soligenix, Inc. (SNGX) announced financial results for the second quarter of 2024 and provided a business update. The company...
198 Views
SNGX: Phase 3 Trial of HyBryte in CTCL to Initiate in 2H24
On August 9, 2024, Soligenix, Inc. (SNGX) announced financial results for the second quarter of 2024 and provided a business update. The company...
215 Views